Russ Conroy

The regulatory agency has set a Prescription Drug User Fee Act date of April 23, 2024 for N-803 plus BCG as a treatment for BCG-unresponsive, non–muscle invasive bladder carcinoma.

Data from the phase 3 RATIONALE-301 trial appear to support tislelizumab as a potential frontline treatment option for patients with unresectable hepatocellular carcinoma.

Data from the phase 3 JUPITER-02 study and phase 2 POLARIS-02 study support the FDA approval of toripalimab-tpzi alone and in combination with gemcitabine and cisplatin in nasopharyngeal carcinoma.

Paige Lymph Node is the first artificial intelligence application of its kind to receive breakthrough device designation from the FDA for detecting breast cancer metastases.

Investigators will assess the safety and preliminary anti-tumor activity of ONCT-534 in metastatic castration-resistant prostate cancer in the phase 1/2 study ONCT-534-101.

Findings from a phase 2 trial also show that there is no progression-free survival or overall survival benefit with lapatinib plus chemoradiotherapy in patients with non-human papillomavirus–related head and neck cancer.

The primary end point of overall response rate is met in the phase 2 ROSEWOOD study of patients with relapsed/refractory follicular lymphoma receiving zanubrutinib plus obinutuzumab vs obinutuzumab monotherapy.

Data from a phase 2 trial suggests that earlier use of abiraterone acetate/prednisone plus cabazitaxel may elicit clinical benefit in patients with metastatic castration-resistant prostate cancer.

A yoga intervention program in patients with head and neck cancer appears to correlate with significantly fewer feeding tube placements compared with those receiving usual care.

ERBB2, FAT3, and FRS2 alterations appear to correlate with improved progression-free survival with ribociclib compared with placebo in patients with advanced breast cancer.

Treatment with mRNA-4157 plus pembrolizumab yields benefits in resected melanoma subgroups in the phase 2 KEYNOTE-942 trial, including those with BRAF-mutated tumors.

Central nervous system progression-free survival appears to be longer with trastuzumab deruxtecan than with comparator treatment in those with HER2-positive metastatic breast cancer and brain metastases.

Findings from a secondary data analysis suggest a need for further research to determine risk factors that place younger patients who are Puerto Rican at a high risk of endometrial cancer.

Adding durvalumab to standard-of-care chemotherapy appears to improve downstaging in patients with resectable gastric cancer and gastroesophageal junction cancer in the phase 3 MATTERHORN study.

Data from a phase 1a/1b trial support additional research on dual TIGIT/PD-L1 inhibition in patients with advanced solid tumors.

Data from the phase 3 ECHELON-1 trial support the European Commission’s approval of brentuximab vedotin plus chemotherapy as a treatment for those with CD30-positive stage III Hodgkin lymphoma.

Developers plan to assess onvansertib plus standard of care as a frontline treatment for patients with metastatic pancreatic ductal adenocarcinoma in an investigator-initiated trial.

A real-world study found most patients with lower-risk myelodysplastic syndrome do not appear to require dose escalations of luspatercept.

Approval of the CRCdx RAS Mutation Detection Kit may improve access to panitumumab for the treatment of patients with colorectal cancer.

Rates of treatment discontinuation appear to be higher in patients receiving nivolumab plus ipilimumab for cancer than those receiving nivolumab monotherapy.

The FDA companion diagnostic designation for the FoundationOne CDx and FoundationOne Liquid CDx may improve access to treatment with encorafenib plus binimetinib for those with BRAF V600E-mutated non–small cell lung cancer.

Findings from a meta-analysis highlight the effect of varying censorship criteria for the definition of surrogate end points in localized prostate cancer randomized clinical trials.

Findings from the phase 3 TARGET-TP trial support a biomarker-driven primary thromboprophylaxis strategy in adult patients with lung and gastrointestinal cancers as routine care.

Nivolumab is now available as an adjuvant treatment for patients with completely resected stage IIB or IIC melanoma following its approval by the FDA based on data from the phase 3 CheckMate-76k trial.

Adding TPST-1120 to atezolizumab and bevacizumab appears to improve progression-free survival compared with atezolizumab and bevacizumab alone in patients with hepatocellular carcinoma.

Data from the phase 2 SAMCO-PRODIGE 54 trial may support the use of immune checkpoint inhibitors over standard second-line therapy in mismatch repair–deficient and/or microsatellite instability–high metastatic colorectal cancer.

Data from a phase 1 study support the orphan drug designation for SLS009 as a treatment for patients with acute myeloid leukemia.

The FDA companion diagnostic designation for FoundationOne CDx may improve access to treatment with selpercatinib in select patients with solid tumors harboring a RET gene fusion.

CAR-HEMATOTOX scores may enable risk stratification of patients with mantle cell lymphoma prior to treatment with brexucabtagene autoleucel.

Elevated white blood cell counts also appear to correlate with shorter overall survival in patients receiving standard induction chemotherapy plus cytarabine for acute myeloid leukemia.